3-Year efficacy and durability of simplification to single tablet regimens: a comparison between co-formulated efavirenz/emtricitabine/tenofovir and rilpivirine/emtricitabine/tenofovir.

Abstract:

BACKGROUND:Few data are available about efficacy and durability of simplification from multi-tablet antiretroviral regimens to co-formulated efavirenz (EFV)/emtricitabine (FTC)/tenofovir (TDF) versus rilpivirine (RPV)/FTC/TDF in virologically suppressed HIV-1-infected patients. METHODS:We retrospectively analysed HIV-infected patients with HIV RNA <50 copies/ml switching to co-formulated EFV/FTC/TDF or RPV/FTC/TDF at five Italian centres. Patients were followed from time of switch until regimen discontinuation or a maximum of 3-years follow-up. Time to treatment discontinuation (TD) and virological failure (VF; defined as two consecutive HIV RNA >50 copies/ml or a single determination >1,000 copies/ml) and their predictors were investigated. RESULTS:1,560 patients were reviewed of which 1,097 (70%) switched to EFV/FTC/TDF and 463 (30%) to RPV/FTC/TDF. During follow-up, VF and TD occurred in 44 (4%) and 242 (22%) patients in EFV/FTC/TDF and in 29 (6%) and 50 (11%) patients in RPV/FTC/TDF, respectively. The 3-year estimated probability of remaining free from VF was 96.2% with EFV/FTC/TDF versus 92.7% with RPV/FTC/TDF (P=0.003). At multivariate analysis, regimen type (EFV/FTC/TDF versus RPV/FTC/TDF aHR 0.24; P=0.004) and time of virological suppression (aHR 0.85; P=0.048) were the only independent predictors of VF. The estimated 3-year probability of remaining free from TD was 77.4% with EFV/FTC/TDF versus 88.4% with RPV/FTC/TDF (P=0.001). Predictors of TD were female sex, switching from PI-based regimens, older age, shorter time of virological suppression and regimen type (EFV/FTC/TDF versus RPV/FTC/TDF aHR 2.48; P<0.001). RPV/FTC/TDF showed a safer lipid profile and a greater increase in creatinine. CONCLUSIONS:Both regimens showed good safety and efficacy in this real-life setting, although switch to RPV/FTC/TDF seemed better tolerated while EFV/FTC/TDF was associated with a lower probability of VF.

journal_name

Antivir Ther

journal_title

Antiviral therapy

authors

Gagliardini R,Bandera A,Zaccarelli M,Sterrantino G,Latini A,D'Avino A,Lapadula G,Antinori A,Cauda R,De Luca A,Gori A,Di Giambenedetto S,Fabbiani M

doi

10.3851/IMP3188

subject

Has Abstract

pub_date

2018-01-01 00:00:00

pages

139-148

issue

2

eissn

1359-6535

issn

2040-2058

journal_volume

23

pub_type

杂志文章,多中心研究
  • Effect of individual cognitive behaviour intervention on adherence to antiretroviral therapy: prospective randomized trial.

    abstract:OBJECTIVE:A high level of adherence to antiretroviral therapy is required for complete suppression of HIV replication, immunological and clinical effectiveness. We investigated whether cognitive behaviour therapy can improve medication adherence. DESIGN:Prospective randomized 1-year trial. SETTING:Collaboration of HI...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Weber R,Christen L,Christen S,Tschopp S,Znoj H,Schneider C,Schmitt J,Opravil M,Günthard HF,Ledergerber B,Swiss HIV Cohort Study.

    更新日期:2004-02-01 00:00:00

  • Factors associated with HBV virological breakthrough.

    abstract:BACKGROUND:Little is known about non-adherence to HBV therapy. This study aimed to investigate the relationship between self-reported missed days of antiviral therapy and HBV virological breakthrough and factors associated with virological breakthrough. METHODS:A cross-sectional survey of 211 HBV patients receiving or...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,多中心研究

    doi:10.3851/IMP3087

    authors: Sheppard-Law S,Zablotska-Manos I,Kermeen M,Holdaway S,Lee A,Zekry A,Dore GJ,George J,Maher L

    更新日期:2017-01-01 00:00:00

  • Body image is a major determinant of sexual dysfunction in stable HIV-infected women.

    abstract:BACKGROUND:Prevalence and factors associated with sexual dysfunction in HIV-positive women are poorly known. METHODS:This was a cross-sectional study in a cohort of HIV-infected women. Clinically stable women were invited to participate in a female sexual dysfunction (FSD) evaluation with Female Sexual Function Index ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Luzi K,Guaraldi G,Murri R,De Paola M,Orlando G,Squillace N,Esposito R,Rochira V,Zirilli L,Martinez E

    更新日期:2009-01-01 00:00:00

  • Prevalence of transmitted HIV-1 drug resistance among young adults attending HIV counselling and testing clinics in Kigali, Rwanda.

    abstract:BACKGROUND:Scaling-up antiretroviral therapy (ART) in resource-limited settings has raised concerns of emerging HIV drug resistance (DR) and its transmission to newly infected individuals. To assess the prevalence of transmitted drug resistance (TDR) in recently HIV-infected individuals, a WHO TDR threshold survey was ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP2999

    authors: Mutagoma M,Ndahimana Jd,Kayirangwa E,Dahourou AG,Balisanga H,DeVos JR,McAlister D,Yang C,Bertagnolio S,Riedel DJ,Nsanzimana S

    更新日期:2016-01-01 00:00:00

  • The first wave: HCV NS3 protease inhibitors telaprevir and boceprevir.

    abstract::Boceprevir and telaprevir are peptidomimetic serine protease inhibitors that have been recently approved for the treatment of HCV chronic infection. The addition of these drugs to the prior standard of care, pegylated interferon and ribavirin, improves sustained virological response rates for treatment-naive and treat...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:10.3851/IMP2424

    authors: Marks KM,Jacobson IM

    更新日期:2012-01-01 00:00:00

  • Changes in abdominal fat following antiretroviral therapy initiation in HIV-infected individuals correlate with waist circumference and self-reported changes.

    abstract:BACKGROUND:We examined whether waist circumference (WC) and self-reported abdominal size changes can estimate visceral adipose tissue (VAT) changes for those initiating antiretroviral therapy (ART). METHODS:Prospectively collected data from ACTG A5257 and its metabolic substudy, A5260s, were used for this analysis. AR...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP3148

    authors: Bhagwat P,Ofotokun I,McComsey GA,Brown TT,Moser C,Sugar CA,Currier JS

    更新日期:2017-01-01 00:00:00

  • Impact of CCR5, integrase and protease inhibitors on human endothelial cell function, stress, inflammation and senescence.

    abstract:BACKGROUND:Ageing HIV-infected patients present an increased incidence of cardiovascular diseases, endothelial dysfunction being an early alteration. Some protease inhibitors (PIs) have been shown to increase the risk of cardiovascular disease. We evaluated here the effects of CCR5 or integrase inhibitors as compared t...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP3160

    authors: Afonso P,Auclair M,Caron-Debarle M,Capeau J

    更新日期:2017-01-01 00:00:00

  • Long-term lamivudine treatment is associated with a good maintained response in severe acute exacerbation of chronic HBeAg-negative hepatitis B.

    abstract::Hepatitis B e antigen (HBeAg)-negative chronic hepatitis B is difficult to treat and there is little long-term data for lamivudine treatment of severe acute exacerbation. We report a prospective, consecutive cohort of severe acute exacerbation of HBeAg-negative chronic hepatitis B patients treated by lamivudine betwee...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章

    doi:

    authors: Chan HL,Wong VW,Hui AY,Tsang SW,Chan JL,Chan HY,Wong GL,Sung JJ

    更新日期:2006-01-01 00:00:00

  • Maternal antiretroviral prophylaxis and breastfeeding.

    abstract::The prevention of mother-to-child transmission of HIV-1 during breastfeeding is a major concern in resource-poor settings where alternatives to breast milk may be unaffordable, unsafe and limited by social stigma. The use of triple-drug antiretroviral regimens initiated during pregnancy and continued throughout breast...

    journal_title:Antiviral therapy

    pub_type: 评论,杂志文章

    doi:10.3851/IMP2314

    authors: Marzolini C,Gray GE

    更新日期:2012-01-01 00:00:00

  • Ribavirin monitoring in chronic hepatitis C therapy: anaemia versus efficacy.

    abstract::The standard treatment of HCV infection with pegylated interferon-alpha2a or -alpha2b and ribavirin is effective in <50% of HCV genotype-1-infected patients. To improve this figure, it might be desirable to obtain optimal plasma concentrations of the drug by increasing the dose. Unfortunately, there is great interpati...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:10.3851/IMP1609

    authors: Brochot E,Castelain S,Duverlie G,Capron D,Nguyen-Khac E,François C

    更新日期:2010-01-01 00:00:00

  • Outcome of lamivudine-resistant chronic hepatitis B after up to 5 years of combination therapy with adefovir.

    abstract:BACKGROUND:There is a paucity of data on the long-term efficacy of combination lamivudine and adefovir therapy in patients with lamivudine-resistant chronic hepatitis B. METHODS:We determined the cumulative virological, serological and biochemical outcomes of 165 lamivudine-resistant chronic hepatitis B patients on la...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP2335

    authors: Seto WK,Liu K,Fung J,Wong DK,Yuen JC,Hung IF,Lai CL,Yuen MF

    更新日期:2012-01-01 00:00:00

  • Viro-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice.

    abstract:BACKGROUND:Virological success (VS) and immunological reconstitution (IR) of antiretroviral-naive HIV-1-infected patients with pre-therapy viral load (VL) >500,000 copies/ml was assessed after 12 months of treatment according to initial drug-class regimens. METHODS:An observational multicentre retrospective study was ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP3197

    authors: Santoro MM,Di Carlo D,Armenia D,Zaccarelli M,Pinnetti C,Colafigli M,Prati F,Boschi A,Antoni AMD,Lagi F,Sighinolfi L,Gervasoni C,Andreoni M,Antinori A,Mussini C,Perno CF,Borghi V,Sterrantino G

    更新日期:2018-01-01 00:00:00

  • Kinetics of productive and latent HIV infection in lymphatic tissue and peripheral blood during triple-drug combination therapy with or without additional interleukin-2.

    abstract:OBJECTIVE:To study decay rates of productively and latently infected cells in peripheral blood and lymph nodes during triple antiretroviral therapy and the possible impact of interleukin-2 (IL-2) on viral kinetics. METHODS:In this non-randomized study, nine antiretroviral-naive HIV-positive patients received either sa...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Stellbrink HJ,Hufert FT,Tenner-Racz K,Lauer J,Schneider C,Albrecht H,Racz P,van Lunzen J

    更新日期:1998-01-01 00:00:00

  • Ribavirin priming improves the virological response to antiviral treatment in transplanted patients with recurrent hepatitis C: a pilot study.

    abstract:INTRODUCTION:Patients with hepatitis C recurrence after liver transplantation represent a clinical challenge. Antiviral treatment in transplant patients has usually poor tolerability and limited efficacy, with a mean sustained virological response (SVR) of 30%. Our pilot study was aimed at evaluating whether 8-week rib...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP1834

    authors: Merli M,Giannelli V,Gentili F,Giusto M,Simmaco M,Lionetto L,Corradini SG,Biliotti E,Attili AF,Rossi M,Taliani G

    更新日期:2011-01-01 00:00:00

  • Real-world evidence for nucleoside/nucleotide analogues in a 5-year multicentre study of antiviral-naive chronic hepatitis B patients in China: 52-week results.

    abstract:BACKGROUND:In China, the clinical management of chronic hepatitis B (CHB) is complicated by the use of variousnucleoside/nucleotide analogue (NUC) regimens in treatment-naive patients, including NUCs with low genetic barriers to resistance, with/without add-on therapy and de novo NUC combinations. This longitudinal obs...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.3851/IMP3205

    authors: Jia J,Tang H,Ning Q,Jiang J,Dou X,Zhang M,Zhang S,Shang J,Lu W,Ye Y,Wang X,Li M,Liu J,Bo Q,Tan W,EVOLVE Study Group.

    更新日期:2018-01-01 00:00:00

  • Altered heterochromatin organization after perinatal exposure to zidovudine.

    abstract:BACKGROUND:Zidovudine (3'-azido-3'-deoxythymidine, AZT), administered to pregnant women alone or in combination with other antiretroviral drugs, greatly reduces the mother-to-child transmission of HIV-1. The potential genotoxicity of these molecules is underestimated and wide-ranging evaluation of its biological and cl...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Senda S,Blanche S,Costagliola D,Cibert C,Nigon F,Firtion G,Floch C,Parat S,Viegas-Péquignot E

    更新日期:2007-01-01 00:00:00

  • External quality assessment of HLA-B*5701 reporting: an international multicentre survey.

    abstract:OBJECTIVES:HLA-B*5701 strongly predicts abacavir hypersensitivity (HSR), but implementation of effective routine screening into clinical practice requires testing be practical and accurate. We tested the proficiency of HLA-B*5701 typing among laboratories using sequence-specific primer PCR. DESIGN AND METHODS:DNA pane...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,多中心研究

    doi:

    authors: Hammond E,Almeida CA,Mamotte C,Nolan D,Phillips E,Schollaardt TA,Gill MJ,Angel JB,Neurath D,Li J,Giulivi T,McIntyre C,Koultchitski G,Wong B,Reis M,Rachlis A,Cole DE,Chew CB,Neifer S,Lalonde R,Roger M,Jeanneau A

    更新日期:2007-01-01 00:00:00

  • Serum hepatitis B surface antigen concentration correlates with HBV DNA level in patients with chronic hepatitis B.

    abstract:BACKGROUND:Serum HBV DNA level is crucial in the management of chronic hepatitis B (CHB); however, the assay is expensive and cannot be used widely. Therefore, we explored the possibility of hepatitis B surface antigen (HBsAg) quantification as a surrogate marker for HBV DNA level in CHB patients. METHODS:A total of 2...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,随机对照试验

    doi:10.3851/IMP1696

    authors: Su TH,Hsu CS,Chen CL,Liu CH,Huang YW,Tseng TC,Liu CJ,Chen PJ,Lai MY,Chen DS,Kao JH

    更新日期:2010-01-01 00:00:00

  • Neither boosted elvitegravir nor darunavir with emtricitabine/tenofovir disoproxil fumarate increase insulin resistance in healthy volunteers: results from the STRIBILD-IR study.

    abstract:BACKGROUND:Insulin resistance (IR) was one of the first reported complications in HIV-positive patients who were receiving antiretroviral therapy (ART). However, the metabolic effects of newer fixed-dose ART combinations are unclear. METHODS:This Phase I prospective randomized open-label study evaluated the effects on...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,随机对照试验

    doi:10.3851/IMP3049

    authors: Spinner CD,Kern KE,Zink A,Wolf E,Balogh A,Noe S,Von Werder A,Schwerdtfeger C,Schmid RM,Iakoubov R

    更新日期:2016-01-01 00:00:00

  • Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113).

    abstract:BACKGROUND:Although thiazolidinediones have been shown to increase subcutaneous fat in congenital lipodystrophy, rosiglitazone did not show convincing results in HIV lipoatrophy. We assess a potential specific effect of pioglitazone in this setting. METHODS:One-hundred and thirty HIV-1-infected adults with self-report...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:

    authors: Slama L,Lanoy E,Valantin MA,Bastard JP,Chermak A,Boutekatjirt A,William-Faltaos D,Billaud E,Molina JM,Capeau J,Costagliola D,Rozenbaum W

    更新日期:2008-01-01 00:00:00

  • Short communication. Baseline factors associated with haematological toxicity that leads to a dosage reduction of pegylated interferon-alpha2a and ribavirin in HIV- and HCV-coinfected patients on HCV antiviral therapy.

    abstract:OBJECTIVE:To assess the baseline factors associated with haematological toxicity that lead to ribavirin or pegylated interferon (peginterferon) dosage reductions in hepatitis C and human immunodeficiency virus (HCV/HIV)-coinfected patients. DESIGN:Multicentre, prospective, observational study. SETTING:Eleven hospital...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章,多中心研究

    doi:

    authors: Fuster D,Huertas JA,Gómez G,Solà R,González García J,Vilaró J,Pedrol E,Force L,Tor J,Sirera G,Videla S,Planas R,Clotet B,Tural C,PEG-TOX Research Group.

    更新日期:2005-01-01 00:00:00

  • Persistent brain abnormalities in antiretroviral-naive HIV patients 3 months after HAART.

    abstract:BACKGROUND:Proton magnetic resonance spectroscopy (1H-MRS) and neuropsychological tests may be useful for monitoring the effectiveness of highly active antiretroviral therapy (HAART) in HIV-associated brain injury. We aimed to evaluate whether brain abnormalities will improve 3 months after HAART. METHOD:Thirty-three ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Chang L,Ernst T,Witt MD,Ames N,Walot I,Jovicich J,DeSilva M,Trivedi N,Speck O,Miller EN

    更新日期:2003-02-01 00:00:00

  • Modelling hepatitis C virus kinetics: the relationship between the infected cell loss rate and the final slope of viral decay.

    abstract:BACKGROUND:Patients infected with hepatitis C virus (HCV) who respond to treatment with interferon-alpha plus ribavirin exhibit biphasic or triphasic viral load decreases. While the rapid first phase is indicative of the effectiveness of therapy in blocking viral production (epsilon), the slope of the final phase (lamb...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Dahari H,Shudo E,Cotler SJ,Layden TJ,Perelson AS

    更新日期:2009-01-01 00:00:00

  • Prevalence and clinical implications of insertions in the HIV-1 p6Gag N-terminal region in drug-naive individuals initiating antiretroviral therapy.

    abstract::We assessed the prevalence and clinical impact of insertions within the HIV-1 p6Gag proline-rich (PTAP) region on initial antiretroviral therapy response in 461 HIV-infected, drug-naive individuals initiating therapy in British Columbia, Canada between June 1996 and August 1998. HIV p6Gag insertions were detected by n...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Brumme ZL,Chan KJ,Dong WW,Wynhoven B,Mo T,Hogg RS,Montaner JS,O'Shaughnessy MV,Harrigan PR

    更新日期:2003-04-01 00:00:00

  • Is there a need for liver disease monitoring in HIV patients in Africa?

    abstract::Liver disease is one of the leading causes of death in HIV-infected individuals from Europe and North America and has been attributed mainly to coinfection with hepatotropic viruses. Little data, however, has so far become available on liver disease in HIV-infected individuals from Africa. Results from a first study o...

    journal_title:Antiviral therapy

    pub_type: 评论,杂志文章

    doi:10.3851/IMP1787

    authors: Rockstroh JK,Peters L,Wedemeyer H

    更新日期:2011-01-01 00:00:00

  • Association between systemic inflammation and obstructive sleep apnea in men with or at risk for HIV infection.

    abstract:BACKGROUND:We sought to determine whether markers of systemic inflammation are associated with the presence of moderate/severe obstructive sleep apnea (OSA) and whether this association differs based on HIV and HIV treatment status. METHODS:HIV-uninfected men (HIV-; n=60), HIV-infected men receiving HAART (HIV+/HAART;...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,多中心研究

    doi:10.3851/IMP2745

    authors: Brigham EP,Patil SP,Jacobson LP,Margolick JB,Godfrey R,Johnson J,Johnson-Hill LM,Reynolds S,Schwartz AR,Smith PL,Brown TT

    更新日期:2014-01-01 00:00:00

  • Plasma lopinavir concentrations predict virological failure in a cohort of South African children initiating a protease-inhibitor-based regimen.

    abstract:BACKGROUND:Poor adherence to antiretroviral therapy contributes to pharmacokinetic variability and is the major determinant of virological failure. However, measuring treatment adherence is difficult, especially in children. We investigated the relationship between plasma lopinavir concentrations, pretreatment characte...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP2749

    authors: Moholisa RR,Schomaker M,Kuhn L,Meredith S,Wiesner L,Coovadia A,Strehlau R,Martens L,Abrams EJ,Maartens G,McIlleron H

    更新日期:2014-01-01 00:00:00

  • Lifetime cost of HIV care in France during the era of highly active antiretroviral therapy.

    abstract:OBJECTIVE:To estimate the treatment and health care costs of HIV infection or AIDS in France during the era of highly active antiretroviral therapy (HAART). DESIGN:We used a clinical database of HIV-infected patients to calculate the resource use and cost of care for different stages of HIV infection. Costs were incor...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Yazdanpanah Y,Goldie SJ,Losina E,Weinstein MC,Lebrun T,Paltiel AD,Seage GR 3rd,Leblanc G,Ajana F,Kimmel AD,Zhang H,Salamon R,Mouton Y,Freedberg KA

    更新日期:2002-12-01 00:00:00

  • A pilot case-control study of zidovudine compared with zidovudine plus didanosine in patients with advanced HIV-1 disease and no previous experience with antiretrovirals.

    abstract::Although zidovudine (ZDV) is effective in HIV-1-infected patients, the duration of its efficacy may be short when treatment is started in advanced HIV disease. This pilot prospective case-control study was designed to evaluate the combination of ZDV plus didanosine [ddI] compared with ZDV monotherapy as an initial the...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章

    doi:

    authors: Gatell JM,Leal M,Mallolas J,Vidal C,Pumarola T,Parra R,Padró S,Caruz A,Falgueras T,Rey C,Sánchez-Quijano A,Torres Y,Lissen E,Jiménez de Anta MT,Soriano E

    更新日期:1996-04-01 00:00:00

  • HIV-1 genital shedding in HIV-infected patients randomized to second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir.

    abstract:BACKGROUND:HIV-1 shedding in genital secretions is associated with HIV transmission risk. Limited data exist on the effect of second-line lopinavir/ritonavir monotherapy (mLPV/r) on genital secretion of HIV RNA. METHODS:We measured HIV-1 in genital secretions of HIV-infected adults at time of failure from non-nucleosi...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章

    doi:10.3851/IMP2737

    authors: Bunupuradah T,Bowonwattanuwong C,Jirajariyavej S,Munsakul W,Klinbuayaem V,Sophonphan J,Mahanontharit A,Hirschel B,Ruxrungtham K,Ananworanich J,HIV STAR Study team.

    更新日期:2014-01-01 00:00:00